CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients

IntroductionImmunotherapy has limited efficacy in metastatic colorectal cancer (mCRC). Understanding mechanisms mediating immune resistance in microsatellite stable (MSS) colorectal tumors remains an ongoing challenge. Novel combination immunotherapy-based approaches have been developed under the ra...

Full description

Bibliographic Details
Main Authors: Stefania Napolitano, Giulia Martini, Davide Ciardiello, Massimo Di Maio, Nicola Normanno, Antonio Avallone, Erika Martinelli, Evaristo Maiello, Teresa Troiani, Fortunato Ciardiello
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Oncology
Subjects:
mCRC
rechallenge
cetuximab
avelumab
phase II trial
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.940523/full

Similar Items

Similar Items